It is a routine procedure to treat diseases like TTP that lack critical plasma components (e.g., the vWF-cleaving protease—ADAMTS13), or diseases that are characterized by pathognomonic circulating factors that need to be removed (e.g., myasthenia gravis and AChR-Ab) [78]. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.